Sign In
Last checked at 
26 Jan 2026 12:10
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Result of AGM
Oxford, UK - 26 January 2026 - Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces that all resolutions proposed at the Company's Annual General Meeting, held earlier today, were duly passed. The proxy votes received for the AGM were as shown below:
Resolution | Votes for | % | Votes against | % | Chairman's Discretion | % | Abstentions / Votes withheld |
|
Ordinary Resolutions | ||||||||
1. To receive the financial statements and the reports of the Directors and the Auditors for the year ended 30 September 2025 | 1,913,765,673 | 99.96 | 13,252 | 0.00 | 722,754 | 0.04 | 687,222 |
|
2. To approve the report of the Remuneration Committee for the year ended 30 September 2025 | 1,200,415,738 | 62.71 | 713,218,083 | 37.26 | 722,754 | 0.04 | 832,326 |
|
3. To elect Peter Presland as a Director of the Company | 1,910,939,324 | 99.82 | 2,808,322 | 0.15 | 722,754 | 0.04 | 718,501 |
|
4. To re-elect Dr Alexandre Akoulitchev as a Director of the Company | 1,910,863,980 | 99.81 | 2,881,251 | 0.15 | 722,754 | 0.04 | 720,916 |
|
5. To re-elect Dr David Holbrook as a Director of the Company | 1,199,722,309 | 62.67 | 714,042,922 | 37.30 | 722,754 | 0.04 | 700,916 |
|
6. To re-elect Iain Ross as a Director of the Company | 1,907,689,355 | 99.64 | 6,075,280 | 0.32 | 722,754 | 0.04 | 701,512 |
|
7. To re-elect Paul Stockdale as a Director of the Company | 1,910,898,407 | 99.81 | 2,866,824 | 0.15 | 722,754 | 0.04 | 700,916 |
|
8. To re-appoint Grant Thornton UK LLP as Auditors of the Company | 1,913,079,280 | 99.93 | 676,192 | 0.04 | 722,754 | 0.04 | 710,675 |
|
9. To authorise the Directors to set the remuneration of the Auditor | 1,911,916,081 | 99.87 | 1,827,754 | 0.10 | 722,754 | 0.04 | 722,312 |
|
10. To authorise the Directors to allot shares in the Company | 1,910,460,099 | 99.80 | 3,113,162 | 0.16 | 722,754 | 0.04 | 892,886 |
|
Special Resolutions | ||||||||
11. To disapply statutory pre-emption rights in connection with a rights issue or other pre-emptive issue | 1,845,833,984 | 96.42 | 67,888,556 | 3.55 | 722,754 | 0.04 | 743,607 |
|
12. To disapply statutory pre-emption rights in connection with an acquisition or a specified capital investment | 1,846,582,870 | 96.46 | 67,136,765 | 3.51 | 722,754 | 0.04 | 746,512 |
|
13. To authorise the Company to make market purchases of its own shares | 1,852,677,167 | 96.77 | 61,083,956 | 3.19 | 722,754 | 0.04 | 705,024 |
|
The Board notes the proportion of shareholders' votes which were against ordinary resolutions two and five. The Board intends to consult with shareholders to understand their views.
-Ends-
For further details please contact:
Oxford BioDynamics Plc | Tel: +44 (0)1865 518910 |
Iain Ross Executive Chairman Paul Stockdale, CFO | |
Shore Capital - Nominated Adviser and Broker | Tel: +44 (0)20 7408 4090 |
Stephane Auton / Lucy Bowden | |
OAK Securities - Joint Broker | Tel: +44 (0)20 3973 3678 |
Matthew Clarke / Tim Dainton / Calvin Man | |
Camarco - Financial PR | Tel: +44 (0)20 3757 4980 |
Marc Cohen / Tilly Butcher / Fergus Young | OBDFinancial@camarco.co.uk |
Notes to Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.
Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.
The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.
OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.
The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.
Follow the stocks
